175 related articles for article (PubMed ID: 38220492)
1. [What's new in hyperkalemia management?].
Lefevre F; Mousseaux C; Bobot M
Rev Med Interne; 2024 Jun; 45(6):350-353. PubMed ID: 38220492
[TBL] [Abstract][Full Text] [Related]
2. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
Natale P; Palmer SC; Ruospo M; Saglimbene VM; Strippoli GF
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013165. PubMed ID: 32588430
[TBL] [Abstract][Full Text] [Related]
3. Sodium zirconium cyclosilicate reconciles management of hyperkalemia and continuity of renin-angiotensin-aldosterone system inhibitors: a retrospective observational study.
Kimura W; Minatoguchi S; Mizuno T; Koide S; Hayashi H; Hasegawa M; Inaguma D; Tsuboi N
J Nephrol; 2024 Jan; 37(1):171-179. PubMed ID: 37608241
[TBL] [Abstract][Full Text] [Related]
4. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.
Palmer BF
Mayo Clin Proc; 2020 Feb; 95(2):339-354. PubMed ID: 31668450
[TBL] [Abstract][Full Text] [Related]
5. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
Santoro A; Mandreoli M
G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
[TBL] [Abstract][Full Text] [Related]
6. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
Schaefer JA; Gales MA
Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
[TBL] [Abstract][Full Text] [Related]
7. New drugs to prevent and treat hyperkalemia.
Lepage L; Desforges K; Lafrance JP
Curr Opin Nephrol Hypertens; 2016 Nov; 25(6):524-528. PubMed ID: 27584929
[TBL] [Abstract][Full Text] [Related]
8. Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD.
Lepage L; Dufour AC; Doiron J; Handfield K; Desforges K; Bell R; Vallée M; Savoie M; Perreault S; Laurin LP; Pichette V; Lafrance JP
Clin J Am Soc Nephrol; 2015 Dec; 10(12):2136-42. PubMed ID: 26576619
[TBL] [Abstract][Full Text] [Related]
9. Advances in treatment of hyperkalemia in chronic kidney disease.
Sarafidis PA; Georgianos PI; Bakris GL
Expert Opin Pharmacother; 2015; 16(14):2205-15. PubMed ID: 26330193
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
Takkar C; Nassar T; Qunibi W
Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634
[TBL] [Abstract][Full Text] [Related]
11. Hyperkalemia in chronic kidney disease: a focus on potassium lowering pharmacotherapy.
Sampani E; Theodorakopoulou M; Iatridi F; Sarafidis P
Expert Opin Pharmacother; 2023; 24(16):1775-1789. PubMed ID: 37545002
[TBL] [Abstract][Full Text] [Related]
12. Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent.
Rastogi A; Hanna RM; Mkrttchyan A; Khalid M; Yaqoob S; Shaffer K; Dhawan P; Nobakht N; Kamgar M; Goshtaseb R; Sarmosyan K; Gnarini M; Wassef O; Lerma E
Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1055-1064. PubMed ID: 34227913
[TBL] [Abstract][Full Text] [Related]
13. Patiromer for the treatment of hyperkalemia.
Colbert GB; Patel D; Lerma EV
Expert Rev Clin Pharmacol; 2020 Jun; 13(6):563-570. PubMed ID: 32511052
[TBL] [Abstract][Full Text] [Related]
14. Patiromer: a clinical review.
Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR
Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884
[TBL] [Abstract][Full Text] [Related]
15. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
[TBL] [Abstract][Full Text] [Related]
16. The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia.
Pitt B; Garza D
Expert Opin Drug Saf; 2018 May; 17(5):525-535. PubMed ID: 29667438
[TBL] [Abstract][Full Text] [Related]
17. Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders.
Sarwar CMS; Bhagat AA; Anker SD; Butler J
Handb Exp Pharmacol; 2017; 243():537-560. PubMed ID: 28382468
[TBL] [Abstract][Full Text] [Related]
18. Managing Hyperkalemia: Stepping Into a New Frontier.
Pham AQ; Sexton J; Wimer D; Rana I; Nguyen T
J Pharm Pract; 2017 Oct; 30(5):557-561. PubMed ID: 27609505
[TBL] [Abstract][Full Text] [Related]
19. Novel Agents for the Prevention and Management of Hyperkalemia.
McCullough PA; Costanzo MR; Silver M; Spinowitz B; Zhang J; Lepor NE
Rev Cardiovasc Med; 2015; 16(2):140-55. PubMed ID: 26198561
[TBL] [Abstract][Full Text] [Related]
20. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
Tamargo J; Caballero R; Delpón E
Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
